These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34862252)

  • 1. Pharmacokinetics, Mass Balance, and Metabolism of the Novel Urate Transporter 1 Inhibitor [
    Zheng Y; Zhang H; Liu M; Li G; Ma S; Zhang Z; Lin H; Zhan Y; Chen Z; Zhong D; Miao L; Diao X
    Drug Metab Dispos; 2022 Jun; 50(6):798-808. PubMed ID: 34862252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic Study on the Species Differences in Excretion Pathway of HR011303 in Humans and Rats.
    Guo Z; Liu M; Meng J; Xue Y; Huang Q; Zheng Y; Wu Y; Chen Z; Yu J; Zhong D; Li G; Chen X; Diao X
    Drug Metab Dispos; 2022 Jun; 50(6):809-818. PubMed ID: 34862251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans.
    Lee CA; Yang C; Shah V; Shen Z; Wilson DM; Ostertag TM; Girardet JL; Hall J; Gillen M
    Drug Metab Dispos; 2018 May; 46(5):532-541. PubMed ID: 29490903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotransformation Pathways and Metabolite Profiles of Oral [
    Pusalkar S; Zhou X; Li Y; Cohen L; Yang JJ; Balani SK; Xia C; Shyu WC; Lu C; Venkatakrishnan K; Chowdhury SK
    Drug Metab Dispos; 2020 Mar; 48(3):217-229. PubMed ID: 31911485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Disposition, and Biotransformation of [
    Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
    Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An LC-MS/MS method for quantification of HR011303, a novel highly selective urate transporter 1 inhibitor in beagle dogs and the application to a pharmacokinetic study.
    Wang J; Yao W; Fan D; Qiu Z; Song J; Pan K; Hang T
    Biomed Chromatogr; 2019 Oct; 33(10):e4604. PubMed ID: 31128076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Human UDP-Glucuronosyltransferase and Sulfotransferase as Responsible for the Metabolism of Dotinurad, a Novel Selective Urate Reabsorption Inhibitor.
    Omura K; Motoki K; Kobashi S; Miyata K; Yamano K; Iwanaga T
    Drug Metab Dispos; 2021 Nov; 49(11):1016-1024. PubMed ID: 34380635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
    Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
    Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, Metabolism, and Excretion of [
    Yamada M; Mendell J; Takakusa H; Shimizu T; Ando O
    Drug Metab Dispos; 2019 Mar; 47(3):340-349. PubMed ID: 30541878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
    Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
    Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass balance study of [14C] rabeprazole following oral administration in healthy subjects.
    Setoyama T; Drijfhout WJ; van de Merbel NC; Humphries TJ; Hasegawa J
    Int J Clin Pharmacol Ther; 2006 Nov; 44(11):557-65. PubMed ID: 17176622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, mass balance, and metabolism of [
    Zheng YD; Zhang H; Zhan Y; Bian YC; Ma S; Gan HX; Lai XJ; Liu YQ; Gong YC; Liu XF; Sun HB; Li YG; Zhong DF; Miao LY; Diao XX
    Acta Pharmacol Sin; 2021 Sep; 42(9):1535-1546. PubMed ID: 33244163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism, excretion, and pharmacokinetics of [
    Yamamura N; Mendel-Harary J; Brown K; Uchiyama M; Urasaki Y; Takahashi M; Warren V; Vashi V
    Xenobiotica; 2021 May; 51(5):549-563. PubMed ID: 33487061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass balance study of [
    Ge X; Ma S; Yan S; Wu Y; Chen C; Tang C; Zhan Y; Bian YC; Shen K; Feng S; Gao X; Zhong D; Zhang H; Miao LY; Diao XX
    Xenobiotica; 2023 Feb; 53(2):69-83. PubMed ID: 36745485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
    Vourvahis M; Gleave M; Nedderman AN; Hyland R; Gardner I; Howard M; Kempshall S; Collins C; LaBadie R
    Drug Metab Dispos; 2010 May; 38(5):789-800. PubMed ID: 20124396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
    Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
    Glaenzel U; Jin Y; Hansen R; Schroer K; Rahmanzadeh G; Pfaar U; Jaap van Lier J; Borell H; Meissner A; Camenisch G; Zhao S
    Drug Metab Dispos; 2020 Oct; 48(10):873-885. PubMed ID: 32665418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Disposition and Metabolism of Bempedoic Acid, a Potent Inhibitor of ATP Citrate Lyase, in Healthy Human Subjects.
    Amore BM; Cramer C; MacDougall D; Emery MG
    Drug Metab Dispos; 2023 May; 51(5):599-609. PubMed ID: 36878717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption, metabolism and excretion of [
    Vuu I; Dahal UP; Wang Z; Shen X; Rodgers J; Wahlstrom J; Houk B
    Cancer Chemother Pharmacol; 2022 Oct; 90(4):357-367. PubMed ID: 36063185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.